<DOC>
	<DOCNO>NCT01835938</DOCNO>
	<brief_summary>Chronic Hepatitis C Virus ( HCV ) infection major cause liver cirrhosis hepatocellular carcinoma world-wide . Current combination therapy pegylated interferon-alfa , ribavirin protease inhibitor limit resistance substantial side effect . The investigator identify epidermal growth factor receptor ( EGFR ) host factor HCV infection . Inhibition kinase function EGFR approve inhibitor Erlotinib ( TarcevaTM ) broadly inhibit HCV infection major genotype include viral escape variant resistant host immune response . Completed preclinical proof-of-concept study HCV cell culture animal model system demonstrate inhibition EGFR function Erlotinib constitute novel antiviral approach prevention treatment HCV infection ( European patent application EP 08 305 604.4 , Filing date : September 26 , 2008 ; Inserm , Paris , France Lupberger et al . Nature Medicine 2011 ) . Since Erlotinib ( TarcevaTM ) establish approved drug cancer treatment well characterize safety profile human , aim study investigate safety , efficacy pharmacokinetics Erlotinib , first-in-class entry inhibitor , treatment HCV infection randomize placebo-controlled double blind clinical trial patient chronically infected HCV . Following completion , trial set stage investigation entry inhibitor antiviral combination standard care direct antiviral HCV protease inhibitor . Thus , randomize clinical trial important step development novel urgently need antiviral therapy overcome resistance .</brief_summary>
	<brief_title>Clinical Investigation Erlotinib HCV Entry Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Chronic genotype 1b hepatitis C infection detectable HCV RNA ( &gt; 1x104 UI/mL ) Na√Øve , relapser nonresponder interferon without ribavirin Weight &gt; 45kg , BMI 18 25 Kg/m2 liver biopsy liver FibroScan eliminate presence cirrhosis year enrollment , Nonsmoker occasional smoker ( ie &lt; 3 cig/day ) HIV HBV infection Cirrhosis Liver decompensation Chronic liver disease non relate HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Hepatitis C Virus infection</keyword>
	<keyword>entry inhibitor</keyword>
	<keyword>kinase inhibitor</keyword>
</DOC>